Anzeige
Mehr »
Dienstag, 13.01.2026 - Börsentäglich über 12.000 News
Kritischer Rohstoff, westliche Knappheit, hohe Gehalte: Steht hier die nächste strategische Neubewertung bevor?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12EKB | ISIN: CA09073K1084 | Ticker-Symbol: 20B
Frankfurt
12.01.26 | 08:23
0,272 Euro
-0,73 % -0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOMARK DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
BIOMARK DIAGNOSTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2760,32012.01.

Aktuelle News zur BIOMARK DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
BIOMARK DIAGNOSTICS Aktie jetzt für 0€ handeln
31.12.25Biomark Diagnostics Inc: Biomark looks back at 2025, sets out 2026 vision1
31.12.25BioMark Diagnostics, Inc.: BioMark: 2025 Achievements & 2026 Vision330Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
30.12.25Biomark Diagnostics Inc: Biomark appoints Lavender as director1
30.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors229Vancouver, British Columbia--(Newsfile Corp. - December 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy...
► Artikel lesen
23.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program289Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer...
► Artikel lesen
01.12.25BioMark Diagnostics, Inc.: BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala297Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early...
► Artikel lesen
13.11.25Biomark Diagnostics Inc: Biomark talks CCS plan to reduce lung cancer mortality1
12.11.25BioMark Diagnostics, Inc.: BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy388Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - November is Lung Cancer Awareness Month, and BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading...
► Artikel lesen
08.10.25Biomark Diagnostics Inc: Biomark platform selected for German lung cancer trial1
07.10.25BioMark Diagnostics, Inc.: BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial340Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early...
► Artikel lesen
30.09.25Biomark Diagnostics Inc: Biomark obtains Asia patents for lung cancer test1
29.09.25BioMark Diagnostics, Inc.: BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy316Vancouver, British Columbia--(Newsfile Corp. - September 29, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for...
► Artikel lesen
13.08.25Biomark Diagnostics Inc: Biomark enters partnership with Sama in Tunisia1
12.08.25BioMark Diagnostics, Inc.: BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership431Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer...
► Artikel lesen
06.08.25Biomark Diagnostics Inc: Biomark expands Quebec lab, doubles testing capacity1
05.08.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships493Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer...
► Artikel lesen
30.07.25BioMark Diagnostics, Inc.: BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026491Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests...
► Artikel lesen
20.05.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology554Vancouver, British Columbia--(Newsfile Corp. - May 20, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leader in developing liquid biopsy tests for early cancer...
► Artikel lesen
12.05.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test427Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer...
► Artikel lesen
08.05.25BioMark Diagnostics, Inc.: BioMark Diagnostics Announces Uplisting to OTCQB Venture Market327Vancouver, British Columbia--(Newsfile Corp. - May 8, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1